In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found no ...

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced positive 24-month results from the Phase 3 GATHER2 clinical trial evaluating the efficacy and safety of Izervay (avacincaptad pegol ...

A new campaign for Astellas Pharma’s Izervay is aimed at opening retina specialists’ eyes to the unique role they play in their geographic atrophy (GA) patients’ lives. The “Partners in Protection” ...

In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med Izervay has nabbed a much-needed label update from the FDA. The agency lifted ...

Please provide your email address to receive an email when new articles are posted on . Izervay received a permanent J-code from CMS. The code, J2782, goes into effect April 1. CMS has assigned a ...

Please provide your email address to receive an email when new articles are posted on . Izervay is now approved without limitation on duration of dosing. The approval is based on data from the phase 3 ...

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced results from the GATHER2 Phase 3 clinical trial, demonstrating Izervay (avacincaptad pegol intravitreal solution) continued to reduce the rate ...

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the supplemental new drug application (sNDA) of Astellas Pharma’s IZERVAY (avacincaptad pegol intravitreal ...

Over 2 years, only a slight increased incidence of choroidal neovascularization was observed for IZERVAY pooled vs. sham; in year 2, incidence of CNV was similar for IZERVAY EOM vs. sham "GA is a ...

Credit: Iveric Bio. Izervay is expected to be available in 2 to 4 weeks. The Food and Drug Administration (FDA) has approved Izervay ™ (avacincaptad pegol intravitreal solution) for the treatment of ...